NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ABVC

ABVC BioPharma Inc

Jun 30 • 04:00PM ET

2.22

Dollar change -0.37
Percentage change -14.09	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN VRTX REGN GILD BIIB MRNA BMY PFE JNJ LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.14	Insider Own	14.33%	Shs Outstand	15.38M	Perf Week	13.52%
Market Cap	37.78M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	14.55M	Perf Month	58.93%
Enterprise Value	42.50M	PEG	-	EPS next Q	-	Inst Own	1.69%	Short Float	3.49%	Perf Quarter	158.72%
Income	-1.81M	P/S	74.08	EPS this Y	-	Inst Trans	-58.04%	Short Ratio	1.16	Perf Half Y	336.27%
Sales	0.51M	P/B	6.33	EPS next Y	-	ROA	-12.26%	Short Interest	0.51M	Perf YTD	277.12%
Book/sh	0.35	P/C	46.07	EPS next 5Y	-	ROE	-27.00%	52W High	2.60 -14.42%	Perf Year	203.42%
Cash/sh	0.05	P/FCF	-	EPS past 3/5Y	56.56% 27.39%	ROIC	-32.52%	52W Low	0.40 456.25%	Perf 3Y	-76.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	12.72% -6.20%	Gross Margin	38.22%	Volatility	12.34% 10.82%	Perf 5Y	-92.33%
Dividend TTM	-	EV/Sales	83.33	EPS Y/Y TTM	93.72%	Oper. Margin	-384.33%	ATR (14)	0.21	Perf 10Y	-
Dividend Ex-Date	Sep 16, 2013	Quick Ratio	0.22	Sales Y/Y TTM	1904.43%	Profit Margin	-356.42%	RSI (14)	62.52	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	86.06%	SMA20	19.45%	Beta	0.37	Target Price	20.20
Payout	-	Debt/Eq	0.55	Sales Q/Q	-100.00%	SMA50	52.76%	Rel Volume	2.24	Prev Close	2.59
Employees	19	LT Debt/Eq	0.03	Earnings	-	SMA200	168.07%	Avg Volume	437.87K	Price	2.22
IPO	Nov 10, 2004	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	955,045	Change	-14.09%

Jun-26-25 08:00AM	ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology (NewMediaWire)
Jun-24-25 08:00AM	ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment (NewMediaWire) +5.10%
Jun-06-25 08:30AM	ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million (NewMediaWire)
Jun-03-25 06:00AM	ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value (NewMediaWire) +7.14%
May-14-25 09:00AM	ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance (NewMediaWire) -13.10%
09:00AM	Loading…
May-09-25 09:00AM	ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504 (NewMediaWire) -8.33%
May-01-25 08:30AM	ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan (NewMediaWire)
Apr-16-25 09:00AM	UPDATE: ABVC BioPharma Announces 2024 Financial Results (NewMediaWire) +8.34%
Apr-15-25 04:30PM	ABVC BioPharma Announces 2024 Financial Results (NewMediaWire)
Apr-03-25 09:00AM	ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million (NewMediaWire) -17.24%
Mar-19-25 09:00AM	ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential (NewMediaWire)
Mar-05-25 04:01PM	ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs (NewMediaWire)
Feb-26-25 04:01PM	ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets (NewMediaWire) +13.86%
Feb-20-25 09:00AM	ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025 (NewMediaWire)
Feb-12-25 08:30AM	Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion (NewMediaWire)
08:30AM	Loading…
Jan-16-25 08:30AM	ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference (NewMediaWire)
Jan-15-25 08:30AM	ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market (NewMediaWire) +5.68%
Jan-14-25 08:30AM	AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees (NewMediaWire)
Jan-13-25 09:00AM	ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement (NewMediaWire)
Jan-07-25 08:30AM	ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products (NewMediaWire) -14.86%
Jan-02-25 09:00AM	ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market (NewMediaWire) +8.69%
Dec-19-24 08:30AM	ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 (GlobeNewswire) +6.74%
Dec-11-24 06:30AM	ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners (GlobeNewswire) +9.50%
Nov-14-24 09:00AM	ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones (GlobeNewswire)
Oct-22-24 08:45AM	ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners (GlobeNewswire)
Aug-15-24 07:30AM	ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements (GlobeNewswire) -5.19%
Jul-18-24 10:31AM	ABVC BioPharma's CEO Discusses New Drug Development and AI Integration (News Direct)
Jul-09-24 07:16AM	ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI (NewMediaWire)
Jul-02-24 09:00AM	ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals (NewMediaWire) -8.16%
Jun-25-24 09:00AM	ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market (NewMediaWire)
09:20AM	Loading…
Jun-12-24 09:20AM	ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue (NewMediaWire)
May-24-24 09:00AM	Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M (NewMediaWire) -9.09%
May-22-24 09:00AM	ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M (NewMediaWire)
May-17-24 10:52PM	ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024 (InvestorPlace)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
09:25AM	Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M (NewMediaWire)
May-09-24 09:35AM	Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M (NewMediaWire)
Apr-18-24 09:25AM	AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share (GlobeNewswire)
Apr-17-24 09:00AM	ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M (GlobeNewswire) -8.93%
Apr-10-24 08:30AM	ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M (GlobeNewswire)
Mar-26-24 08:30AM	ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M (GlobeNewswire) +21.90%
Mar-21-24 08:30AM	AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars (GlobeNewswire)
Mar-19-24 08:30AM	ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine (GlobeNewswire)
Mar-14-24 09:30AM	ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update (GlobeNewswire)
Feb-27-24 08:30AM	ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars (GlobeNewswire)
Feb-15-24 08:30AM	ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues (GlobeNewswire)
Feb-12-24 08:30AM	ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Feb-08-24 09:17AM	ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share (GlobeNewswire) -7.14%
Jan-03-24 07:24AM	ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees (GlobeNewswire) +60.83%
Dec-07-23 08:30AM	ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.41%
Dec-05-23 08:30AM	ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials (GlobeNewswire)
Nov-21-23 08:30AM	ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market (GlobeNewswire) +5.33%
Nov-16-23 10:05AM	ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M (GlobeNewswire) +27.20%
Nov-15-23 09:00AM	ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results (GlobeNewswire) +11.61%
Oct-26-23 08:30AM	ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million (GlobeNewswire) +50.59%
Oct-17-23 08:30AM	ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study (GlobeNewswire) -7.00%
Oct-09-23 08:30AM	ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Aug-23-23 08:30AM	ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study (GlobeNewswire)
Aug-17-23 09:19AM	ABVC Executes Cooperation Agreement for Strategic Investments (GlobeNewswire) -7.22%
Aug-10-23 08:30AM	ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -8.82%
Aug-07-23 08:30AM	ABVC Corporate Update and CEO's Letter to Shareholders (GlobeNewswire) -5.47%
Aug-03-23 09:20AM	ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration (GlobeNewswire)
Aug-01-23 08:30AM	ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales (GlobeNewswire) +44.98%
Jul-31-23 09:30AM	ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering (GlobeNewswire) -7.43%
Jul-27-23 09:22AM	ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering (GlobeNewswire) -41.73%
Jul-26-23 08:30AM	ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments (GlobeNewswire) +40.00%
Jul-24-23 12:30PM	ABVC BioPharma Announces Reverse Stock Split (GlobeNewswire)
Jul-06-23 08:30AM	The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency (GlobeNewswire) -6.49%
Jun-26-23 08:30AM	ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth (GlobeNewswire) +7.54%
Jun-20-23 08:30AM	ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production (GlobeNewswire) +7.90%
Jun-12-23 08:30AM	ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF (GlobeNewswire)
Jun-06-23 08:30AM	ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization (GlobeNewswire)
May-22-23 08:30AM	ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia (GlobeNewswire) -5.42%
May-04-23 08:30AM	ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Apr-26-23 08:30AM	ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF (GlobeNewswire)
Apr-10-23 08:30AM	ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) (GlobeNewswire)
Apr-06-23 08:30AM	ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand (GlobeNewswire)
Mar-31-23 06:49PM	ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results (GlobeNewswire)
Mar-20-23 07:00AM	ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand (PR Newswire) +8.32%
Mar-14-23 07:00AM	ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare (PR Newswire) +11.21%
Feb-28-23 08:30AM	ABVC BioPharma Provides 2023 Pipeline Update (GlobeNewswire)
Feb-23-23 04:16PM	ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials (GlobeNewswire)
Feb-21-23 08:30AM	ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® (GlobeNewswire) +6.21%
Jan-19-23 08:30AM	ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference (GlobeNewswire)
Jan-18-23 08:25AM	ABVC: Several Potential Paths to Achieving Near-Term Milestones (Zacks Small Cap Research) -6.04%
Jan-05-23 08:30AM	FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer (GlobeNewswire) +72.58%
Dec-20-22 11:05AM	ABVC: Key Medical Venues Participating in Clinical Studies (Zacks Small Cap Research)
Nov-17-22 08:30AM	ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval (GlobeNewswire)
05:16AM	ABVC BioPharma Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 06:20PM	ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results (GlobeNewswire)
Nov-07-22 08:30AM	ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) (GlobeNewswire)
Nov-02-22 08:30AM	Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharmas Medication for Treating Depression in Cancer Patients (GlobeNewswire)
Oct-05-22 08:30AM	ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia (GlobeNewswire)
Sep-23-22 08:30AM	ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval (GlobeNewswire) +12.72%
Sep-16-22 09:36AM	ABVC: Moving Lead Assets Forward and Expanding Development Pipeline (Zacks Small Cap Research) -27.00%
Sep-13-22 08:30AM	ABVC Biopharma Announces Letter to Shareholders (GlobeNewswire)
Sep-09-22 08:30AM	ABVC BioPharma Selects Additional Vitargus® Phase II Study Site (GlobeNewswire)
Aug-22-22 08:30AM	ABVC Provides Oncology Pipeline Updates (GlobeNewswire)
Aug-18-22 08:30AM	ABVC BioPharma Provides Vitargus® Update (GlobeNewswire) +19.62%
Aug-15-22 05:48PM	ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results (GlobeNewswire) -5.76% +7.11%

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABVC

ABVC BioPharma Inc

Upgrade your FINVIZ experience